David A. Siegel Phathom Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 51,600 shares of PHAT stock, worth $531,480. This represents 0.0% of its overall portfolio holdings.

Number of Shares

51,600

Previous 22,700 127.31%

Holding current value

$531,480

Previous $207,000 164.25%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$6.21 - $11.05 $179,469 - $319,345	28,900 Added 127.31%	51,600 $547,000
Q4 2023 Feb 14, 2024	BUY	$6.99 - $10.71 $158,673 - $243,117	22,700 New	22,700 $207,000
Q4 2022 Feb 14, 2023	SELL	$9.18 - $11.53 $85,374 - $107,229	-9,300 Reduced 38.59%	14,800 $166,000
Q3 2022 Nov 14, 2022	SELL	$6.46 - $12.11 $56,848 - $106,568	-8,800 Reduced 26.75%	24,100 $267,000
Q2 2022 Aug 15, 2022	SELL	$6.2 - $15.5 $31,620 - $79,050	-5,100 Reduced 13.42%	32,900 $278,000

Q1 2022 May 16, 2022	BUY	$11.55 - $20.06 $68,145 - $118,353	5,900 Added 18.38%	38,000 $517,000
Q4 2021 Feb 14, 2022	BUY	$17.83 - $33.15 $279,931 - $520,455	15,700 Added 95.73%	32,100 $631,000
Q3 2021 Nov 15, 2021	SELL	$30.69 - $36.83 $279,279 - $335,153	-9,100 Reduced 35.69%	16,400 $526,000
Q2 2021 Aug 16, 2021	SELL	$32.66 - $39.87 $192,693 - $235,232	-5,900 Reduced 18.79%	25,500 $863,000
Q1 2021 May 17, 2021	BUY	$33.86 - $48.68 $1.06 Million - $1.53 Million	31,400 New	31,400 $1.18 Million

Others Institutions Holding PHAT

# of Institutions

123

Shares Held

54.7M

Call Options Held

34K

Put Options Held

58.7K

View Full List

About Phathom Pharmaceuticals, Inc.

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $404M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

More about PHAT

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account